133 related articles for article (PubMed ID: 10448949)
1. Determination of the catechol-O-methyltransferase inhibitor tolcapone and three of its metabolites in animal and human plasma and urine by reversed-phase high-performance liquid chromatography with ultraviolet detection.
Heizmann P; Schmitt M; Leube J; Martin H; Saner A
J Chromatogr B Biomed Sci Appl; 1999 Jul; 730(2):153-60. PubMed ID: 10448949
[TBL] [Abstract][Full Text] [Related]
2. Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase.
Jorga K; Fotteler B; Heizmann P; Gasser R
Br J Clin Pharmacol; 1999 Oct; 48(4):513-20. PubMed ID: 10583021
[TBL] [Abstract][Full Text] [Related]
3. Determination of the catechol-O-methyltransferase inhibitor Ro 40-7592 in human plasma by high-performance liquid chromatography with coulometric detection.
Timm U; Erdin R
J Chromatogr; 1992 Feb; 593(1-2):63-8. PubMed ID: 1639913
[TBL] [Abstract][Full Text] [Related]
4. Identification of metabolite profiles of the catechol-O-methyl transferase inhibitor tolcapone in rat urine using LC/MS-based metabonomics analysis.
Sun J; Von Tungeln LS; Hines W; Beger RD
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Aug; 877(24):2557-65. PubMed ID: 19615953
[TBL] [Abstract][Full Text] [Related]
5. Interspecies scaling of tolcapone, a new inhibitor of catechol-O-methyltransferase (COMT). Use of in vitro data from hepatocytes to predict metabolic clearance in animals and humans.
Lave T; Dupin S; Schmitt M; Kapps M; Meyer J; Morgenroth B; Chou RC; Jaeck D; Coassolo P
Xenobiotica; 1996 Aug; 26(8):839-51. PubMed ID: 8879148
[TBL] [Abstract][Full Text] [Related]
6. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects.
Dingemanse J; Jorga K; Zürcher G; Fotteler B; Sedek G; Nielsen T; van Brummelen P
Eur J Clin Pharmacol; 1996; 50(1-2):47-55. PubMed ID: 8739811
[TBL] [Abstract][Full Text] [Related]
7. Lack of an effect of Madopar on the disposition of tolcapone and its 3-O-methylated metabolite in rats.
Funaki T; Onodera H; Ushiyama N; Tsukamoto Y; Tagami C; Fukazawa H; Kuruma I
J Pharm Pharmacol; 1995 Jun; 47(6):539-42. PubMed ID: 7674141
[TBL] [Abstract][Full Text] [Related]
8. In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity.
Smith KS; Smith PL; Heady TN; Trugman JM; Harman WD; Macdonald TL
Chem Res Toxicol; 2003 Feb; 16(2):123-8. PubMed ID: 12588182
[TBL] [Abstract][Full Text] [Related]
9. Side effects of the catechol-O-methyl-transferase inhibitor Ro 40-7592 in rabbits.
Garrido JM; Mena MA; Correa C; Herraras O; Jorge P; Leenders K; Antonini A; Günther I; Psylla M; de Yébenes JG
Clin Neuropharmacol; 1994 Jun; 17(3):270-6. PubMed ID: 9316672
[TBL] [Abstract][Full Text] [Related]
10. The disposition of the tolcapone 3-O-methylated metabolite is affected by the route of administration in rats.
Funaki T; Onodera H; Ushiyama N; Tsukamoto Y; Tagami C; Fukazawa H; Kuruma I
J Pharm Pharmacol; 1994 Jul; 46(7):571-4. PubMed ID: 7996385
[TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography in drug evaluation: influence of three different catechol-O-methyltransferase inhibitors on metabolism of [NCA] 6-[18F]fluoro-L-dopa in rhesus monkey.
Günther I; Psylla M; Reddy GN; Antonini A; Vontobel P; Reist HW; Zollinger A; Nickles RJ; Beer HF; Schubiger PA
Nucl Med Biol; 1995 Oct; 22(7):921-7. PubMed ID: 8547890
[TBL] [Abstract][Full Text] [Related]
12. Effect of liver impairment on the pharmacokinetics of tolcapone and its metabolites.
Jorga KM; Kroodsma JM; Fotteler B; Heizmann P; Meyer J; Rasch MC; van Hattum J
Clin Pharmacol Ther; 1998 Jun; 63(6):646-54. PubMed ID: 9663179
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies.
Jorga K; Fotteler B; Banken L; Snell P; Steimer JL
Br J Clin Pharmacol; 2000 Jan; 49(1):39-48. PubMed ID: 10606836
[TBL] [Abstract][Full Text] [Related]
14. Bioanalytical chromatographic methods for the determination of catechol-O-methyltransferase inhibitors in rodents and human samples: a review.
Gonçalves D; Alves G; Soares-da-Silva P; Falcão A
Anal Chim Acta; 2012 Jan; 710():17-32. PubMed ID: 22123108
[TBL] [Abstract][Full Text] [Related]
15. Effects of monoamine oxidase and catechol-O-methyltransferase inhibition on dopamine turnover: a PET study with 6-[18F]L-DOPA.
Doudet DJ; Chan GL; Holden JE; Pate BD; Morrison KS; Calne DB; Ruth TJ
Eur J Pharmacol; 1997 Sep; 334(1):31-8. PubMed ID: 9346324
[TBL] [Abstract][Full Text] [Related]
16. No change of brain extracellular catecholamine levels after acute catechol-O-methyltransferase inhibition: a microdialysis study in anaesthetized rats.
Li YH; Wirth T; Huotari M; Laitinen K; MacDonald E; Männistö PT
Eur J Pharmacol; 1998 Sep; 356(2-3):127-37. PubMed ID: 9774242
[TBL] [Abstract][Full Text] [Related]
17. Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects.
Russ H; Müller T; Woitalla D; Rahbar A; Hahn J; Kuhn W
Naunyn Schmiedebergs Arch Pharmacol; 1999 Dec; 360(6):719-20. PubMed ID: 10619191
[TBL] [Abstract][Full Text] [Related]
18. Determination of endogenous levels of 13-cis-retinoic acid (isotretinoin), all-trans-retinoic acid (tretinoin) and their 4-oxo metabolites in human and animal plasma by high-performance liquid chromatography with automated column switching and ultraviolet detection.
Wyss R; Bucheli F
J Chromatogr B Biomed Sci Appl; 1997 Oct; 700(1-2):31-47. PubMed ID: 9390712
[TBL] [Abstract][Full Text] [Related]
19. Effects of tolcapone upon soluble and membrane-bound brain and liver catechol-O-methyltransferase.
Vieira-Coelho MA; Soares-da-Silva P
Brain Res; 1999 Mar; 821(1):69-78. PubMed ID: 10064789
[TBL] [Abstract][Full Text] [Related]
20. Tolcapone increases maximum concentration of levodopa.
Müller T; Woitalla D; Schulz D; Peters S; Kuhn W; Przuntek H
J Neural Transm (Vienna); 2000; 107(1):113-9. PubMed ID: 10809409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
